

(12) 按照专利合作条约所公布的国际申请

(19) 世界知识产权组织
国际局



(43) 国际公布日:
2005年5月12日(12.05.2005)

PCT

(10) 国际公布号:
WO 2005/042744 A1

(51) 国际分类号⁷: C12N 15/19, C07K 14/52, A61K 38/19, A61P 35/00

(21) 国际申请号: PCT/CN2003/000928

(22) 国际申请日: 2003年11月3日(03.11.2003)

(25) 申请语言: 中文

(26) 公布语言: 中文

(71) 申请人(对除美国以外的所有指定国): 北京沙东生物技术公司(BEIJING SUNBIP BIOTECH CO., LTD.) [CN/CN]; 中国北京市海淀区中关村南大街12号高层5号楼408室, Beijing 100081 (CN).

(72) 发明人: 及

(75) 发明人/申请人(仅对美国): 朱冰(ZHU, Bing) [CN/CN]; 中国北京市海淀区中关村南大街12号高层5号楼408室, Beijing 100081 (CN).

(74) 代理人: 北京纪凯知识产权代理有限公司(JEEKAI & PARTNERS); 中国北京市西城区宣武门西大街甲129号金隅大厦602室, Beijing 100031 (CN).

(81) 指定国(国家): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BC, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

(84) 指定国(地区): ARIPO专利(BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), 欧亚专利(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), 欧洲专利(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI专利(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)


本国际公布:

— 包括国际检索报告。

所引用双字母代码和其它缩写符号, 请参考刊登在每期PCT公报期刊起始的“代码及缩写符号简要说明”。

(54) Title: A RECOMBINANT PROTEIN WITH CANCER SUPPRESSION ACTION, ITS ENCODING GENE AND USE

(54) 发明名称: 一种具有抑癌作用的重组蛋白及其编码基因与应用



(57) Abstract: The present invention discloses a recombinant protein with cancer suppression action, its encoding gene and use. The recombinant protein with cancer suppression action provided by the invention is one of the following proteins: 1) the protein with the amino acid residue sequence of SEQ ID NO:2 in sequence listing; 2) the protein derived from SEQ ID NO:2 which has more than 90% homology to the amino acid residue sequence of SEQ ID NO:2 and has the same activity to SEQ ID NO:2; 3) the protein derived from SEQ ID NO:2 which has obtained from addition or deletion of 15 or no more than 15 amino acid residues in N-terminal of the amino acid residue sequence of SEQ ID NO:2; 4) the protein derived from SEQ ID NO:2 which has obtained from addition or deletion of 15 or no more than 15 amino acid residues in C-terminal of the amino acid residue sequence of SEQ ID NO:2 and has the same activity to SEQ ID NO:2; 5) the protein derived from SEQ ID NO:2 which has replacement, deletion or addition of one or several amino acid residues in the amino acid residue sequence of SEQ ID NO:2 and has the same activity to SEQ ID NO:2. The medicines with above recombinant proteins as active components have obviously selectively suppressive action to tumor cells, not induce apoptosis of normal tissue cells, and have important applicable value.

[见续页]